Afficher la couverture 'Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design | Pellicori, Pierpaolo' en grand format
/5

0 avis

Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design

Archive ouverte

Pellicori, Pierpaolo | Vaduganathan, Muthiah | Ferreira, João, Pedro | Zannad, Faiez | Sanyal, Arun, J

Edité par CCSD ; Wiley -

International audience. The natural history of non-alcoholic fatty liver disease (NAFLD) is still not fully elucidated. Patients with NAFLD have a low risk of liver complications, unless substantial liver fibrosis has developed. On the other hand, NAFLD has been linked with excess metabolic and cardiovascular complications. Therapies targeting common pathways may benefit both NAFLD and underlying cardiometabolic risk. Therefore, there is a rationale for considering cardiovascular endpoints in the context of NAFLD trials and, vice-versa, to consider the concomitant presence of NAFLD in drug development for cardiometabolic disorders. This manuscript provides a framework for consideration for future trials examining the inter-relationship between cardiovascular disease and NAFLD.

Suggestions

Du même auteur

Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

Archive ouverte | Ravassa, Susana | CCSD

International audience. Aims: The HOMAGE randomized trial found that spironolactone reduced left atrial volume index (LAVI), E:A ratio, and a marker of collagen type I synthesis (procollagen type I C-terminal propep...

The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial

Archive ouverte | Verdonschot, Job, a J | CCSD

International audience. Background: Adipose tissue influences the expression and degradation of circulating biomarkers. We aimed to identify the biomarker profile and biological meaning of biomarkers associated with...

Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

Archive ouverte | Verdonschot, Job, a J | CCSD

International audience. Abstract Background Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The “Heart OMics in AGEing” (HOMAGE) trial suggested that spironolactone had b...

Chargement des enrichissements...